microRNA-based biomarkers and the diagnosis of Alzheimer's disease (AD)

Frontiers in Neurology

Volumn 6, Issue JUN, 2015, Pages

  Zhao, Yuhai ^a,b   Bhattacharjee, Surjyadipta ^a   Dua, Prerna ^c   Alexandrov, Peter N ^d   Lukiw, Walter J ^a,b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

^d INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Aging; Alzheimer's disease; Diagnostic panel; Heterogeneity; Human biochemical individuality; Inflammation; microRNA (miRNA); Prion disease

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD33 ANTIGEN; CLATHRIN ASSEMBLY PROTEIN; CLUSTERIN; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT FACTOR H; MEMBRANE RECEPTOR; MESSENGER RNA; MICRORNA; MICRORNA 34A; NEUROPEPTIDE RECEPTOR; PHOSPHATIDYLINOSITOL BINDING CLATHRIN ASSEMBLY PROTEIN; PRESENILIN 1; PRESENILIN 2; SORTILIN RELATED RECEPTOR; TAU PROTEIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

AFRICAN AMERICAN; AGING; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BEHAVIOR DISORDER; BLOOD ANALYSIS; BODY FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COGNITIVE DEFECT; COMORBIDITY; DEMENTIA; DISEASE MARKER; DOWN REGULATION; ENVIRONMENTAL EXPOSURE; ETHNIC DIFFERENCE; FAMILY HISTORY; GENE CONTROL; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC VARIABILITY; HERITABILITY; HUMAN; INNATE IMMUNITY; LIFESTYLE; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROANATOMY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL EXPOSURE; ONSET AGE; PATHOGENESIS; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RISK FACTOR; RNA STRUCTURE; SENILE PLAQUE; UPREGULATION;

EID: 84936929218     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00162     Document Type: Article

References (58)

1. Schipper HM, Maes OC, Chertkow HM, Wang E. MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul Syst Bio. 1:263-274 (2007).
2. Lukiw WJ. MiRNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 18:297-300. (2007).
3. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, Prinjha RK, Richardson JC, Saunders AM, Roses AD, Richards CA. Identification of miRNA changes in Alzheimer's brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis. 14:27-41 (2008).
4. Lukiw WJ, Handley P, Wong L, Crapper McLachlan DR. BC200 RNA in normal human neocortex, non-Alzheimer dementia (NAD), and senile dementia of the Alzheimer type (AD). Neurochem Res. 17:591-597 (1992).
5. Jiang T, Yu JT, Tian Y, Tan L. Epidemiology and etiology of Alzheimer's disease: from genetic to non-genetic factors. Curr Alzheimer Res. 10:852-867 (2013).
6. Guerreiro RJ, Gustafson DR, Hardy J. The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol Aging. 33:437-456 (2012).
7. Canobbio I, Abubaker AA, Visconte C, Torti M, Pula G. Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer's disease. Front Cell Neurosci. 9:65. doi: 10.3389/fncel.2015.00065 (2015).
8. 3: Kim DH, Yeo SH, Park JM, Choi JY, Lee TH, Park SY, Ock MS, Eo J, Kim HS, Cha HJ. Genetic markers for diagnosis and pathogenesis of Alzheimer's disease. Gene. 545:185-193 (2014).
9. Lukiw WJ. Variability in micro RNA (miRNA) abundance, speciation and complexity amongst different human populations and potential relevance to Alzheimer's disease (AD). Front Cell Neurosci. 7:133. doi:10.3389/fncel.2013.00133. (2013)
10. Sherva R, Tripodis Y, Bennett DA, Chibnik LB, Crane PK, de Jager PL, Farrer LA, Saykin AJ, Shulman JM, Naj A, Green RC; GENAROAD Consortium; Alzheimer's disease neuroimaging initiative; Alzheimer's disease genetics consortium. Genome-wide association study of the rate of cognitive decline in Alzheimer's disease. Alzheimers Dement. 10:45-52. doi:10.1016/j.jalz.2013.01.008 (2014).
11. Jin SC, Carrasquillo MM, Benitez BA, Skorupa T, Carrell D, Patel D, Lincoln S,Krishnan S, Kachadoorian M, Reitz C, Mayeux R, Wingo TS, Lah JJ, Levey AI,Murrell J, Hendrie H, Foroud T, Graff-Radford NR, Goate AM, Cruchaga C, Ertekin-Taner N. TREM2 is associated with increased risk for Alzheimer's disease in African Americans. Mol Neurodegener. 10:19-26 (2015)
12. Barnes J, Dickerson B, Frost C, Jiskoot LC, Wolk D, van der Flier WM. Alzheimer's disease first symptoms are age dependent: Evidence from the NACC data set. Alzheimers Dement. doi:10.1016/j.jalz.2014.12.007. (2015).
13. Verhülsdonk S, Hellen F, Höft B, Supprian T, Lange-Asschenfeldt C. Attention and CERAD test performances in cognitively impaired elderly subjects. Acta Neurol Scand. 131:364-371. doi: 10.1111/ane.12346 (2015).
14. Praticò D. Alzheimer's disease and the quest for its biological measures. J Alzheimers Dis 33:S237-241. doi: 10.3233/JAD-2012-129023 (2013).
15. Wang Z, Wang J, Zhang H, Mchugh R, Sun X, Li K, Yang QX. Interhemispheric functional and structural disconnection in Alzheimer's disease: a combined resting-state fMRI and DTI Study. PLoS One. 10(5):e0126310. doi:10.1371/journal. pone.0126310 (2015).
16. Walhovd KB, Fjell AM, Espeseth T. Cognitive decline and brain pathology in aging-need for a dimensional, lifespan and systems vulnerability view. Scand J Psychol. 55:244-254. doi: 10.1111/sjop.12120. (2014).
17. Arevalo-Rodriguez I, Smailagic N, Roqué I Figuls M, Ciapponi A, Sanchez-Perez E, Giannakou A, Pedraza OL, Bonfill Cosp X, Cullum S. Mini-Mental state examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 3:CD010783. doi: 10.1002/14651858.CD010783.pub2 (2015).
18. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement. 2015 Jan;11(1):58-69. doi:10.1016/j.jalz.2014.02.004 (2015).
19. Chitravas N, Jung RS, Kofskey DM, Blevins JE, Gambetti P, Leigh RJ, Cohen ML. Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. Ann Neurol. 2011 Sep;70(3):437-44. doi: 10.1002/ana.22454. Epub 2011 Jun 14. PubMed PMID: 21674591; PubMed Central PMCID: PMC3170496.
20. Kim MO, Geschwind MD. Clinical update of Jakob-Creutzfeldt disease. Curr Opin Neurol. 28:302-310. doi: 10.1097/WCO.0000000000000197 (2015).
21. Li JQ, Tan L, Wang HF, Tan MS, Tan L, Xu W, Zhao QF, Wang J, Jiang T, Yu JT. Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis of cohort studies. J Neurol Neurosurg Psychiatry. pii: jnnp-2014-310095. doi: 10.1136/jnnp-2014-310095 (2015).
22. Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1. J Neurosci Res. 70:462-473 (2002).
23. Loring JF, Wen X, Lee JM, Seilhamer J, Somogyi R. A gene expression profile of Alzheimer's disease. DNA Cell Biol. 20:683-695. (2002).
24. Counts SE, Alldred MJ, Che S, Ginsberg SD, Mufson EJ. Synaptic gene dysregulation within hippocampal CA1 pyramidal neurons in mild cognitive impairment. Neuropharmacol 79:172-179 doi:10.1016/j.neuropharm.2013.10.018 (2014).
25. Tan MS, Jiang T, Tan L, Yu JT. Genome-wide association studies in neurology. Ann Transl Med. 2:124. doi: 10.3978/j.issn.2305-5839.2014.11.12. (2014).
26. Chouraki V, Seshadri S. Genetics of Alzheimer's disease. Adv Genet. 87:245-94. doi: 10.1016/B978-0-12-800149- 3.00005-6 (2014).
27. Tai LM, Ghura S, Koster KP, Liakaite V, Maienschein-Cline M, Kanabar P, Collins N, Ben-Aissa M, Lei AZ, Bahroos N, Green SJ, Hendrickson B, Van Eldik LJ, LaDu MJ. APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease. J Neurochem. 133:465-488. doi:10.1111/jnc.13072. (2015).
28. Yaghmoor F, Noorsaeed A, Alsaggaf S, Aljohani W, Scholtzova H, Boutajangout A, Wisniewski T. The role of TREM2 in Alzheimer's and other neurological disorders. J Alzheimers Dis Parkinsonism. 4(5). pii: 160. (2014)
29. Cheng XJ, Gao Y, Zhao YW, Cheng XD. Sodium chloride increases Aβ Levels by Suppressing Aβ clearance in cultured cells. PLoS One. 10:e0130432. doi: 10.1371/journal.pone.0130432 (2015).
30. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimers Dement. 11:718-26. doi:10.1016/j.jalz.2015.05.016. (2015).
31. Østergaard SD, Mukherjee S, Sharp SJ, Proitsi P, Lotta LA, Day F, Perry JR, Boehme KL, Walter S, Kauwe JS, Gibbons LE; Alzheimer's Disease Genetics Consortium; GERAD1 Consortium; EPIC-InterAct Consortium, Larson EB, Powell JF, Langenberg C, Crane PK, Wareham NJ, Scott RA. Associations between potentially modifiable risk factors and Alzheimer disease PLoS Med. 12:e1001841. doi: 10.1371/journal.pmed.1001841 (2015).
32. Bhela S, Mulik S, Reddy PB, Richardson RL, Gimenez F, Rajasagi NK, Veiga-Parga T, Osmand AP, Rouse BT. Critical role of microRNA-155 in herpes simplex encephalitis. J Immunol. 192:2734-2743. doi:10.4049/jimmunol.1302326 (2014).
33. Hill JM, Clement C, Zhao Y, Lukiw WJ. Induction of the pro-inflammatory NF-kB-sensitive miRNA-146a by human neurotrophic viruses. Front Microbiol. 6:43. doi: 10.3389/fmicb.2015.00043. (2015).
34. Alexandrov PN, Zhao Y, Jones BM, Bhattacharjee S, Lukiw WJ. Expression of the phagocytosis-essential protein TREM2 is down-regulated by an aluminum-induced miRNA-34a in a murine microglial cell line. J Inorg Biochem. 128:267-269. doi:10.1016/j.jinorgbio.2013.05.010 (2013).
35. Pogue AI, Percy ME, Cui JG, Li YY, Bhattacharjee S, Hill JM, Kruck TP, Zhao Y,Lukiw WJ. Up-regulation of NFkB- sensitive miRNA-125b and miRNA-146a in metal sulfate-stressed human astroglial (HAG) primary cell cultures. J Inorg Biochem. 105:1434-1437. doi: 10.1016/j.jinorgbio.2011.05.012. (2011).
36. Müller M, Jäkel L, Bruinsma IB, Claassen JA, Kuiperij HB, Verbeek MM. microRNA-29a Is a Candidate Biomarker for Alzheimer's Disease in Cell-Free Cerebrospinal Fluid. Mol Neurobiol. Apr 21. [Epub ahead of print] (2015).
37. Sala Frigerio C, Lau P, Salta E, Tournoy J, Bossers K, Vandenberghe R, Wallin A, Bjerke M, Zetterberg H, Blennow K, De Strooper B. Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease. Neurology 81:2103-6. doi: 10.1212/01.wnl.0000437306.37850.22 (2013).
38. Liu CG, Wang JL, Li L, Wang PC. MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer's disease. Int J Mol Med. 34:160-166. doi: 10.3892/ijmm.2014.1780 (2014).
39. Nagpal N, Kulshreshtha R. miR-191: an emerging player in disease biology. Front Genet. 5:99. doi: 10.3389/fgene.2014.00099 (2014).
40. Wang T, Chen K, Li H, Dong S, Su N, Liu Y, Cheng Y, Dai J, Yang C, Xiao S. The feasibility of utilizing plasma miRNA107 and BACE1 messenger RNA gene expression for clinical diagnosis of amnestic mild cognitive impairment. J Clin Psychiatry. 76:135-141. doi: 10.4088/JCP.13m08812 (2015).
41. Xie B, Zhou H, Zhang R, Song M, Yu L, Wang L, Liu Z, Zhang Q, Cui D, Wang X, Xu S. Serum miR-206 and miR- 132 as potential circulating biomarkers for mild cognitive impairment. J Alzheimers Dis. 45:721-731. doi:10.3233/JAD-142847. (2015).
42. Tan L, Yu JT, Liu QY, Tan MS, Zhang W, Hu N, Wang YL, Sun L, Jiang T, Tan L. Circulating miR-125b as a biomarker of Alzheimer's disease. J Neurol Sci. 336:52-56. doi: 10.1016/j.jns.2013.10.002. (2014).
43. Tiribuzi R, Crispoltoni L, Porcellati S, Di Lullo M, Florenzano F, Pirro M, Bagaglia F, Kawarai T, Zampolini M, Orlacchio A, Orlacchio A. Circulating miR-125b miR128 up-regulation correlates with impaired amyloid β(1-42) degradation in monocytes from patients with sporadic Alzheimer's disease. Neurobiol Aging. 35:345-356. doi: 10.1016/j.neurobiolaging.2013.08.003. (2014).
44. Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, Haas J, Ruprecht K, Paul F, Stähler C, Lang CJ, Meder B, Bartfai T, Meese E, Keller A. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 14:R78. doi: 10.1186/gb-2013-14-7-r78 (2013).
45. Satoh J, Kino Y, Niida S. MicroRNA-Seq Data Analysis Pipeline to Identify Blood Biomarkers for Alzheimer's Disease from Public Data. Biomark Insights. 10:21-31. doi: 10.4137/BMI.S25132. (2015).
46. Burgos K, Malenica I, Metpally R, Courtright A, Rakela B, Beach T, Shill H, Adler C, Sabbagh M, Villa S, Tembe W, Craig D, Van Keuren-Jensen K. Profiles of extracellular miRNA in CSF and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology. PLoS One. 9:e94839. doi:10.1371/journal.pone.0094839. (2014).
47. Gstir R, Schafferer S, Scheideler M, Misslinger M, Griehl M, Daschil N, Humpel C, Obermair GJ, Schmuckermair C, Striessnig J, Flucher BE, Hüttenhofer A. Generation of a neurospecific microarray reveals novel differentially expressed noncoding RNAs in mouse models for neurodegenerative diseases. RNA 20:1929-1943. doi: 10.1261/rna.047225.114 (2014).
48. Kumar RM, Cahan P, Shalek AK, Satija R, Daley Keyser AJ, Li H, Zhang J, Pardee K, Gennert D, Trombetta JJ, Ferrante TC, Regev A, Daley GQ, Collins JJ. Deconstructing transcriptional heterogeneity in pluripotent stem cells. Nature 516:56-61. doi: 10.1038/nature13920 (2014).
49. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt-Rosen O, Suvà ML, Regev A, Bernstein BE. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:1396-1401. doi:10.1126/science.1254257 (2015).
50. Danborg PB, Simonsen AH, Waldemar G, Heegaard NH. The potential of miRNAs as biofluid markers of neurodegenerative disease-a systematic review. Biomarkers19:259-68. doi:10.3109/1354750X.2014.904001 (2014).
51. Wang X, Tan L, Lu Y, Peng J, Zhu Y, Zhang Y, Sun Z. MicroRNA-138 promotes tau phosphorylation by targeting retinoic acid receptor alpha. FEBS Lett. 589:726-729. doi: 10.1016/j.febslet.2015.02.001 (2015).
52. Femminella GD, Ferrara N, Rengo G. The emerging role of microRNAs in Alzheimer's disease. Front Physiol. 6:40. doi: 10.3389/fphys.2015.00040 (2015).
53. D Cheng L, Quek CY, Sun X, Bellingham SA, Hill AF. The detection of microRNA associated with Alzheimer's disease in biological fluids using next-generation sequencing technologies. Front Genet.;4:150. doi:10.3389/fgene.2013.00150 (2013).
54. Koh W, Pan W, Gawad C, Fan HC, Kerchner GA, Wyss-Coray T, Blumenfeld YJ, El-Sayed YY, Quake SR. Noninvasive in vivo monitoring of tissue-specific global gene expression in humans. Proc Natl Acad Sci USA. 111:7361-6. doi: 10.1073/pnas.1405528111 (2014).
55. Grasso M, Piscopo P, Confaloni A, Denti MA. Circulating miRNAs as biomarkers for neurodegenerative disorders. Molecules. 19:6891-6910. doi:10.3390/molecules19056891 (2014).
56. Liu ZP. Reverse Engineering of Genome-wide Gene Regulatory Networks from Gene Expression Data. Curr Genomics. 16:3-22. doi: 10.2174/1389202915666141110210634. (2015).
57. Li Y, Zhang Z. Computational biology in microRNA. Wiley Interdiscip Rev RNA. doi: 10.1002/wrna.1286 (2015).
58. Michaud M, Balardy L, Moulis G, Gaudin C, Peyrot C, Vellas B, Cesari M, Nourhashemi F. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc. 14:877-82. doi: 10.1016/j. jamda. 2013.05.009. PubMed PMID: 23792036 (2013).